AMCAP™
The company leverages over twentyfive years of experience to address the continuously evolving needs of the advanced therapies market.
A key innovation differentiating Anemocyte is its proprietary, patent-pending technology, AMCAP™. AMCAP™ is a game-changing one-pot technology for mRNA synthesis that intelligently merges the crucial steps of transcription and capping into a single, seamless reaction resulting in different key advantages such as increase in efficacy and speed, cost-effectiveness, flexibility and scalability.
AMCAP™ enables the rapid synthesis of high-performance mRNA, positioning Anemocyte at the forefront of the enzymatic capping evolution in mRNA manufacturing for cell and gene therapies needs.
